Clinical Trials Directory

Trials / Completed

CompletedNCT03159741

Investigation of GLP-2 Mechanism of Action (GA-8)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
8 (actual)
Sponsor
University of Copenhagen · Academic / Other
Sex
Male
Age
20 Years – 40 Years
Healthy volunteers
Accepted

Summary

Glucagon-like peptide-2 (GLP-2) is a naturally occuring hormone secreted to the circulation in response to food ingestion. Previous studies have shown that GLP-2 and incretins inhibit the bone resorption. However, the mechanism is unknown. In the present study we will investigate the mechanism of action using a receptor specific inhibitor.

Conditions

Interventions

TypeNameDescription
OTHERInhibitor + GLP-2Inhibitor and GLP-2 are used as study tools.
OTHERPlacebo + GLP-2Placebo and GLP-2 are used as study tools.
OTHERPlacebo + GIPPlacebo and GIP are used as study tools.
OTHERPlacebo + SalinePlacebo

Timeline

Start date
2017-05-16
Primary completion
2017-09-29
Completion
2017-09-29
First posted
2017-05-19
Last updated
2020-01-18

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03159741. Inclusion in this directory is not an endorsement.